Search
forLearn
5 / 801 resultslearn APISCALP™
learn biovolume 128
learn Beta sitsterol
learn oleanolic acid
Research
5 / 690 results
research Evaluation of Atherogenic Indexes in Patients With Lichen Planopilaris: A Case-Control Study
Patients with lichen planopilaris have a higher risk of heart disease.
research Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society
Women with PCOS should be screened for heart disease risk and manage their health to prevent it.
research Contents Vol. 4, 2018
The document focused on hair disorders, especially alopecia, and discussed treatments and impacts on quality of life.
research Atherogenic index of plasma in non-obese women with androgenetic alopecia
Non-obese women with hair loss have higher heart disease risk.
research The utilisation of cardiac risk ratio and non-HDL cholesterol markers to assess cardiovascular risk in type 2 diabetes males with lowered serum DHT
Cardiac risk markers help assess heart risk in males with type 2 diabetes and low DHT.
Community Join
5 / 1000+ resultscommunity Anyone used CB-03-01 (clascoterone), is it worth it, too risky??
The user experienced side effects from low-dose topical finasteride and is considering using clascoterone (CB-03-01) despite concerns about its risks and cost. They seek advice on its effectiveness and potential side effects compared to other treatments like alfatradiol and fluridil.
community cb-03-01 research chem (winlevi/clascoterone cream)
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.
community Clascoterone full results in July
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
community European release of clascoterone
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
community Clascoterone 5% solution infographic
Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.